BTMD trades 43.8% below Wall Street's consensus target of $3.25.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BTMD achieves its forward estimates and maintains a stable P/E multiple of 8.0x. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, biote Corp. (BTMD) has a Wall Street consensus price target of $3.25, based on estimates from 7 covering analysts. With the stock currently trading at $2.25, this represents a potential upside of +43.8%. The company has a market capitalization of $99M.
Analyst price targets range from a low of $2.50 to a high of $4.00, representing a 46% spread in expectations. The median target of $3.25 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BTMD trades at a trailing P/E of 3.0x and forward P/E of 8.0x. Analysts expect EPS to grow -34.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $1.71, with bear and bull scenarios of $1.08 and $2.25 respectively. Model confidence stands at 52/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
HIMSHims & Hers Health, Inc. | $7.4B | $33.54 | $28.08 | -20.8% | Hold | — | 20 |
EVAXEvaxion Biotech A/S | $22M | $3.42 | — | — | — | — | — |
AMWLAmerican Well Corporation | $137M | $8.22 | $6.33 | -24.9% | Hold | — | 15 |
NUVBNuvation Bio Inc. | $2.0B | $5.76 | $13.00 | +133.8% | Buy | — | 9 |
GDRXGoodRx Holdings, Inc. | $891M | $2.57 | $3.08 | +15.8% | Hold | 8.6x | 24 |
DOCSDoximity, Inc. | $3.8B | $20.07 | $29.47 | +44.0% | Hold | 14.3x | 23 |
ABBVAbbVie Inc. | $406.9B | $230.06 | $256.92 | +18.6% | Buy | 15.2x | 41 |
AVDLAvadel Pharmaceuticals plc | $2.1B | $21.64 | $21.43 | -1.0% | Buy | 28.3x | 14 |
TLRYTilray Brands, Inc. | $535M | $4.59 | $10.00 | +111.4% | Hold | — | 20 |
CLOVClover Health Investments, Corp. | $2.7B | $5.14 | $4.47 | -10.6% | Hold | 129.2x | 9 |
Quick answers to the most common questions about buying BTMD stock.
The consensus Wall Street price target for BTMD is $3.25, representing 43.8% upside from the current price of $2.25. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
BTMD has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $3.25 implies 43.8% upside from current levels.
With a forward P/E of 8x, BTMD trades at a relatively low valuation. The consensus target of $3.25 implies 43.8% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $4 for BTMD, while the most conservative target is $2.5. The consensus of $3.25 represents the median expectation. Our quantitative valuation model projects a bull case target of $2 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
BTMD is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BTMD stock forecast based on 7 Wall Street analysts shows a consensus price target of $3.25, with estimates ranging from $2.5 (bear case) to $4 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $2, with bear/bull scenarios of $1/$2.
Our quantitative valuation model calculates BTMD's fair value at $2 (base case), with a bear case of $1 and bull case of $2. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 52/100.
BTMD trades at a forward P/E ratio of 8.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 3.0x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on BTMD, with a "Buy" consensus rating and $3.25 price target (43.8% upside). 6 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BTMD analyst price targets range from $2.5 to $4, a 46% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $3.25 consensus represents the middle ground. Our model's $1-$2 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.